New Open MRI System from Fujifilm Combines Technology Advances with Patient Comfort
The Aperto Lucent open 0.4T MRI platform reportedly offers enhanced fat suppression and spatial resolution capabilities in addition to its open architecture design.
Emphasizing patient comfort, workflow efficiencies and enhanced imaging quality, Fujifilm has launched the Aperto Lucent open 0.4T magnetic resonance imaging (MRI) system.
The system’s wide laterally moving table and single-pillar design are key factors in promoting patient comfort, according to Fujifilm.
In addition to the platform’s permanent magnet technology, the company said the Aperto Lucent provides an array of features to facilitate efficient quality imaging.
In addition to promoting patient comfort, the Aperto Lucent open 0.4T MRI system reportedly provides enhanced fat suppression capabilities and improved spatial resolution. (Image courtesy of Fujifilm.)
• Fat suppression features include eight channels of active patient shimming and chemical shift-selective (CHESS) type radiofrequency (RF) fat saturation, which complements short tau inversion recovery (STIR) sequences.
• A combination of solenoid technology RF receiver coils and the IP-Recon iterative image reconstruction algorithm facilitate a high signal-to-noise ratio (SNR) and enhanced spatial resolution, according to Fujifilm.
• In order to address challenges with patient motion, Fujifilm said the Aperto Lucent system has RADAR motion compensating pulse sequence technology that reduces artifacts and the potential for rescans.
“APERTO Lucent is a perfect solution for providers looking for a space-saving, cost-effective system that enhances the MRI patient experience,” noted Shawn Etheridge, the executive director of modality solutions marketing for Fujifilm Healthcare Americas Corporation. “With permanent magnet open MRI technology, there is little need for additional equipment and infrastructure to maintain the magnetic field, keeping installation and operating costs low for our customers and providing a stronger return on investment.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
